Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
|
|
- Jayson Craig
- 5 years ago
- Views:
Transcription
1 Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
2 Evolution of front line therapy in NSCLC unselected pts 1970 s 1980 s: Treatment until progression 1990 s: Treatment limited to 6 8 courses 2000 s: 3 4 courses of platinum-based therapy. Provided 2nd-line therapy is considered 2010: 4 6 courses of platinum-based therapy + maintenance
3 Strategies for post Platinum therapy
4 Switch Maintenance Concepts of Maintenance 1st-line: Platin-based Combination CR, PR, SD Maintenance Monotherapy with new compound Progression Second Line Treatment JMEN (Pemetrexed) 1 SATURN (Erlotinib) 2 4 cycles until Progression Continuation bis Maintenance Progress 1st-line: Pemetrexed/Cisplatin Pemetrexed/Cisplatin/Bev CR, PR, SD Maintenance Pemetrexed or Pemetrexed/Bev 4 cycles until Progression Progression Second Line Treatment PARAMOUNT 3 AVAPERL 4 Selection of patients with good prognosis Endpoints: Quality of Life Symptom Control Tolerability
5 Gemcitabine vs placebo in NSCLC Primary endpoint: 1. Time to progression Secondary endpoints: 1. ORR 2. Response duration 3. Overall survival 4. Toxicity 5. Symptom control Brodowicz et al. Lung Cancer 52,155,2006
6 Gemcitabine vs Placebo in NSCLC Progression free survival through study period (left) and maintenance phase (right) Brodowicz et al. Lung Cancer 52,155,2006
7 Gemcitabine vs placebo in NSCLC BSC Gem-BSC P-value TTP, overall 5.0 ( ) 6.6 ( ) <0.001 TTP, maintenance 2.0 ( ) 3.6 ( ) <0.001 OS 11 ( ) 13 ( ) Brodowicz et al. Lung Cancer 52,155,2006.
8 Immediate vs delayed docetaxel (Phase III) Fidias, et al. ASCO 2007; Abstract No. LBA7516
9 Probability of PFS Docetaxel Switch Maintenance: PFS HR=0.71 (95% CI: ) p< Delayed Immediate Mos Patients at Risk, n Delayed Immediate Median PFS delayed vs immediate: 2.7 vs 5.7 mos (P =.0001) 48 Fidias PM, et al. J Clin Oncol. 2009;27:
10 Probability of OS Docetaxel Switch Maintenance: OS Delayed Immediate HR=0.84 (95% CI: ) p< Mos Patients at Risk, n Delayed Immediate Median OS delayed vs immediate: 9.7 vs 12.3 mos (P =.0853) 1-yr survival delayed vs immediate: 43.5% vs 51.1% 60 Fidias PM, et al. J Clin Oncol. 2009;27:
11 Pem/BSC vs placebo/bsc in NSCLC: Study design Stage IIIB/IV NSCLC PS 0/1 4 prior cycles of gem, doc, or tax + cis or carb, with CR, PR, or SD (NO PEMETREXED) Randomization factors: gender PS stage best tumor response to induction non-platinum induction drug brain mets 2:1 Randomization Pemetrexed 500 mg/m 2 (d1,q21d) + BSC (N=441)* Primary Endpoint = PFS Placebo (d1, q21d) + BSC (N=222)* *B 12, folate, and dexamethasone given in both arms Ciuleanu, et al. Presented at: Annual Meeting of the American Society of Clinical Oncology, June 2, 2008; Chicago, IL.
12 Progression-free Probability Pem/BSC vs placebo/bsc in NSCLC: Progression-free survival 1.0 N=581 HR=0.599 (95% CI: ) p < Pemetrexed: 4.04 mos (95% CI: ) Placebo: 1.97 mos (95% CI: ) Time (months) 24% censored Ciuleanu, et al. Presented at: Annual Meeting of the American Society of Clinical Oncology, June 2, 2008; Chicago, IL.
13 Maintenance pemetrexed (JMEN): PFS (n=581) OS (n=663) Cielanu et al., Lancet 2010
14 Switch Maintenance: Pemetrexed Response after induction therapy Non squamous NSCLC Induction response CR/PR 0,81 HR Induction response SD 0,61 0,4 0,6 0,8 1,0 HR 1,2 Favours pemetrexed Favours Placebo Belani CP, et al. ASCO 2009 (Abs. CRA8000).
15 Second Line Pemetrexed after Maintenance Gemcitabine or Erlotinib. IFCT-GFPC 0502 Perol et al. Proc ESMO 2010
16 IFCT-GFPC 0502: Treatment Outcomes Outcome Gemcitabine (n = 149) Erlotinib (n = 153) Observation (n = 152) Median PFS, mos HR vs observation (95% CI) 0.55 ( ) 0.82 ( ) P value < Median OS*, mos HR vs observation (95% CI) 0.86 ( ) 0.91 ( ) P value NS NS Perol M, et al. ASCO Abstract 7507.
17 IFCT-GFPC 0502: Treatment Outcomes Perol M. Poster presented at ESMO 2010: PD370
18 IFCT-GFPC 0502: OS Pérol M et al. JCO 2012;30:
19 Switch Maintenance Concepts of Maintenance 1st-line: Platin-based Combination CR, PR, SD Maintenance Monotherapy with new compound Progression Second Line Treatment JMEN (Pemetrexed) 1 SATURN (Erlotinib) 2 4 cykles until Progression Continuation bis Maintenance Progress 1st-line: Pemetrexed/Cisplatin Pemetrexed/Cisplatin/Bev CR, PR, SD Maintenance Pemetrexed or Pemetrexed/Bev 4 cykles until Progression Progression Second Line Treatment PARAMOUNT 3 AVAPERL 4 Selection of patients with good prognosis Endpoints: Quality of Life Symptom Control Tolerability
20 Pemetrexed Continuation-Maintenance (PARAMOUNT) Start of trial medication Induction treatment (4 cycles) days Maintenance treatment (until PD) Progression Inclusion criteria Non-squamous NSCLC Stage IIIB/IV Chemonaïve ECOG PS 0-1 (n=939) Stratification: PS (0 vs. 1) Stage (IIIB vs. IV) before induction Response after induction (CR/PR vs. SD) Pemetrexed 500 mg/m 2 iv q21d Cisplatin 75 mg/m 2 iv q21d CR, PR, SD n=539 PD R 2:1 Pemetrexed 500 mg/m 2 iv q21d n=359 Supplementation with Folic acid and Vitamin B12 in both arms Placebo n=180 Primary endpoint: Progression free survival PS, propensity score; CR, complete response: vollständiges Ansprechen; PR, partial response: teilweises Paz-Ares L, et al. Lancet Oncol 2012; 13:247-55; Ansprechen; SD, stable disease: Krankheitsstabilisierung; Paz-Ares L, et al. J Clin Oncol 2013; 31: ; ClinicalTrials.gov Identifier NCT PD, progressive disease: progressiver Krankheitsverlauf
21 Survival Probability PARAMOUNT: Progression free survival PFS: Primary Efficacy Endpoint PFS: Reassessed at Time of Final OS Survival Probability Pemetrexed Placebo Unadjusted HR: 0.62 ( ) Time (Months) Patients at Risk Pem + BSC Plac+ BSC Patients at Risk Pemetrexed Placebo Unadjusted HR: 0.60 ( ) Time (Months) Pem +BSC Plac + BSC Paz-Ares LG, et al. Lancet Oncology 2012; 13: Paz-Ares LG, et al. J Clin Oncol 2013: 31:
22 Paramount: Overall survival Paz Ares, L. et al J Clin Oncol 2013; 31:
23 Probability of survival Probability of survival All randomized patients (n=539) Stage IV (n=490) Stage IIIB (n=49) Response after induction CR/PR (n=234) Response after Induction SD (n=285) PS 1 before randomisation (n=363) PS 0 before randomisation (n=173) Neversmoker (n=117) smoker (n=418) male (n=313) female (n=226) age <70 (n=447) ager 70 (n=92) age <65 (n=350) age 65 (n=189) Other histology (n=32) Large cell histology (n=36) adenocarcinoma (n=471) PARAMOUNT: OS; Subgroup analysis 0,0 0,5 1,0 1,5 2,0 2,5 Hazard Ratio (95% KI) Favours Pemetrexed Favours Placebo Hazard Ratio 0,78 0,79 0,82 0,81 0,76 0,82 0,70 0,75 0,83 0,82 0,73 0,75 0,89 0,82 0,71 0,81 0,44 0,80 Pemetrexed Placebo CR/PR HR = 0, SD HR = 0, Time since start of maintenance (monthers) CR, complete response: vollständiges Ansprechen; PR, partial response: teilweises Ansprechen; SD, stable disease: Krankheitsstabilisierung; PS, propensity score Paz-Ares L, et al. J Clin Oncol 2012; 30(Suppl):LBA7507
24
25 Efficacy: PFS & OS Trial N Maintenance drug Switch Maintenance PFS HR (95% CI) OS HR (95% CI) Westeel et al. 181 Vinorelbine 0.77 ( ) 1.08 ( ) Fidias et al. 309 Docetaxel 0.71 ( ) 0.84 ( ) Capuzzo 889 Erlotinib 0.71 ( ) 0.81 ( ) Ciuleanu et al. 663 Pemetrexed 0.60 ( ) 0.79 ( ) Continuation Maintenance Paz-Ares et al 539 Pemetrexed 0.62 ( ) NA Brodowicz et al. 206 Gemcitabine 0.69 ( ) 0.84 ( ) Belani et al. 255 Gemcitabine 1.09 ( ) 0.97 ( ) Perol et al. 309 Gemcitabine 0.56 ( ) 0.89 ( )
26 Efficacy: QOL Trial N Maintenance drug Switch Chemotherapy Maintenance Westeel et al. 181 Vinorelbine NR Fidias et al. 309 Docetaxel No differences QoL & Symptom Control Capuzzo 889 Erlotinib Better pain control Cielanu et al. 663 Pemetrexed Better pain and hemoptisis control Continuation Chemotherapy Maintenance Paz-Ares et al 539 Pemetrexed No detrimental effect Brodowicz et al. 206 Gemcitabine NR Belani et al. 255 Gemcitabine NR Perol et al. 309 Gemcitabine NR
27 Antibody maintenance E4599: study design Previously untreated stage IIIB, IV or recurrent predominantly nonsquamous NSCLC (n=878) CP q3w x6 (n=444) Bevacizumab (15mg/kg) + CP q3w x6 (n=434) Bevacizumab PD* PD Primary endpoint overall survival (OS) Secondary endpoints objective response rate progression-free survival (PFS) duration of response safety *No crossover permitted Sandler, et al. N Engl J Med 2006
28 OS estimate E Bev + CP CP CP (n=444) Bevacizumab 15mg/kg + CP (n=434) 0.6 HR (95% CI) 0.79 ( ) p value Median OS (months) Time (months) CP=carboplatin/paclitaxel Sandler, et al. N Engl J Med 2006
29 Pemetrexed or Bevacizumab maintenance? Key patient inclusion criteria No prior systemic treatment ECOG PS 0-1 Stable IIIB-IV nonsquamous NSCLC Stable treated brain mets (n=361) R Induction phase 4 cycles, q3w Pem 500 mg/m 2 + Cb AUC6 (n=182) Stratification PS (0 vs. 1); sex (M vs. F); disease stage (M1a vs. M1b) Pac 200 mg/m 2 + Cb AUC6 + Bev 15 mg/kg (n=179*) Maintenance treatment q3w Pem 500 mg/m 2 (n=98) Bev 15 mg/kg (n=95) PD PD Primary endpoint PFS without Grade 4 AE (G4PFS) Secondary endpoints PFS, OS, RR, DCR Safety and tolerability Zinner et al. J Clin Oncol 31, 2013 (suppl; abstr LBA8003)
30 Proportion Primary Endpoint: G4PFS (ITT) Pem+Cb: Pac+Cb+Bev: median G4PFS = 3.9 mo median G4PFS = 2.9 mo Log-rank p value = HR (90% CI) = 0.85 ( ) Number of G4PFS events Pem+Cb (n=152) % Pac+Cb+Bev (n=144) % G4 AE PD Death Patients at Risk Pem+Cb Pac+Cb+Bev Zinner et al. J Clin Oncol 31, 2013 (suppl; abstr LBA8003)
31 Maintenance with Bevacizumab ± Start of induction treatment Pemetrexed (AVAPERL): Randomised, open phase III trial Progression Induction therapy (4 cycles) Maintenance therapy until PD) Inclusion criteria: Non-squamous NSCLC Stage IIIb/IV No prior treatment n=414 Stratification: gender smoker vs never smoker CR/PR vs. SD Pemetrexed 500 mg/m 2 iv q21d Cisplatin 75 mg/m 2 iv q21d Bevacizumab 7,5 mg/kg iv q21d n=376 CR, PR, SD n=253 PD R Bevacizumab 7,5 mg/kg iv q21d n=125 Pemetrexed 500 mg/m 2 iv q21d Bevacizumab 7,5 mg/kg iv q21d n=128 Primary Endpoint: Progression free survival Barlesi F, et al. J Clin Oncol 2013, e-published ClinicalTrials.gov Identifier NCT
32 Progressionsfreies Überleben ab dem Tag der Randomisierung (%) AVAPERL: PFS from randomisation Therapx PFS (Months) Bev + Pem 7,4 (81 Events) Bev 3,7 (104 Events) HR 0,48 (0,35 0,66); p<0,001 Maintenance Bev+Pem (n=128) Maintenance Bev (n=125) 25 0 Patients at risk Time (months) Bev + Pem Bev Barlesi F, et al. J Clin Oncol 2013, e-published
33 AVAPERL: Overall survival Barlesi et al. Ann. Oncol. 2014
34 POINTBREAK phase III trial 4 cycles Previously untreated, stage IIIB or IV, non-squamous NSCLC, treated CNS mets, PS 0 1 n=939 R 1:1 n=442* Bevacizumab 15 mg/kg q3w n=292 + carboplatin + pemetrexed (66%) n=443* Bevacizumab 15 mg/kg q3w + carboplatin + paclitaxel n=298 (67%) Bevacizumab 15 mg/kg q3w + pemetrexed Bevacizumab 15 mg/kg q3w Treat to PD Treat to PD Primary endpoint OS PI: J Patel *Patient numbers excluding those not treated Secondary endpoints ORR and DCR PFS and TTP safety and QoL Patel, et al. IASLC 2012 (Chicago)
35 OS estimate POINTBREAK: OS (primary endpoint) ITT population Pem + Carbo + Bev Pac + Carbo + Bev HR=1.00 ( ) p= Time (months) Patel, et al. IASLC 2012 (Chicago)
36
37
38 SQUIRE: Study Design Population NECI + Gem-Cis q3w (N=545) CR PR SD NECI q3w PD First-Line Stage IV squamous NSCLC ECOG PS 0-2 R Maximum of 6 cycles Gem-Cis q3w (N=548) PD PD Primary Objective: Overall survival Secondary Objectives: PFS, ORR, safety, QoL Exploratory Objective: EGFR protein expression (IHC, DAKO PharmDx)
39 OS (%) SQUIRE: G/C + Neci vs G/C in Stage IV 1093 pts First-line stage IV SqCLC ECOG PS R SqCLC G/C (1250 mg/m 2 ;75 mg/m 2 ) + Neci 800 mg d 1,8 (n = 545) Maximum of 6 cycles G/C (n = 548) CR PR SD PD Neci PD PD G/C + Neci G/C Stratified HR (95% CI) 0.84 ( ) Stratified P value (log-rank).01 Median OS, mos (95% CI) 11.5 ( ) 9.9 ( ) Mos Thatcher N, et al. Lancet Oncol. 2015;16:
40 Evolution of front line therapy in NSCLC selected pts : molecular selected patients continue treatment until progression: EGFR Alk ROS1 B-RAF
41 Maintenance in Lung Cancer Oncogene Addicted Erlotinib in EGFR m+ NSCLC EURTAC Trial Simulation- EURTAC Trial 4 months treatment X Rosell R et al., Lancet Oncol 2012
42 Evolution of front line therapy in NSCLC selected pts : molecular selected patients continue treatment until progression 2016: PD-L1 positive (>50%) continue pembrolizumab
43 KEYNOTE-024 Study Design (NCT ) Key Eligibility Criteria Untreated stage IV NSCLC PD-L1 TPS 50% ECOG PS 0-1 No activating EGFR mutation or ALK translocation No untreated brain metastases No active autoimmune disease requiring systemic therapy R (1:1) N = 305 Pembrolizumab 200 mg IV Q3W (2 years) Platinum-Doublet Chemotherapy (4-6 cycles) Key End Points Primary: PFS (RECIST v1.1 per blinded, independent central review) Secondary: OS, ORR, safety Exploratory: DOR
44 Progression-Free Survival Events, n Median, mo HR (95% CI) P PFS, % No. at risk Minority received pemetrexed maintenance Assessed per RECIST v1.1 by blinded, independent central review. Data cut-off: May 9, % 50% Pembro Chemo ( ) Time, months 48% 15% <0.001
45 Overall Survival Events, n Median, mo HR (95% CI) P OS, % % 72% No. at risk Pembro 44 NR 0.60 Chemo 64 NR ( ) Time, months 70% 54% Data cut-off: May 9, 2016.
46 Evolution of front line therapy in NSCLC mutation status unknown Platin based chemotherapy Maintenance?
47 Continuation Gefitinib when EGFR mut status is unknown Yang et al. J.Thor. Oncol. 2015
48 Continuation Gefitinib when EGFR mut status is unknown Yang et al. J.Thor. Oncol. 2015
49 Guidelines Maintenance therapy recommended by ESMO ASCO
50 Conclusions Both switch and continuation maintenance chemotherapy prolong PFS and OS Antibody maintenance prolong PFS and OS (?) Small molecule offered untill PD.
Maintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationMaintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationSao Paulo, Abril 2014
Tratamento de Manutencao e outros Sao Paulo, Abril 2014 Rogerio C. Lilenbaum, M.D. Professor of Medicine Yale Cancer Center Chief Medical Officer Smilow Cancer Hospital What Is Maintenance Therapy? Use
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationMaintenance Treatment for Advanced NSCLC. Yvonne Summers PhD, FRCP ESMO Preceptorship Programme March 2017
Maintenance Treatment for Advanced NSCLC Yvonne Summers PhD, FRCP ESMO Preceptorship Programme March 2017 Milestones in the Palliative Systemic Treatment of NSCLC 1990 2000 2010 2015 Platinum based Chemotherapy
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationAntiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab
Micro-ambiente tumorale. Antiangiogenici e immunoterapia: miti e realtà Milano, 11 Ottobre 2016 Antiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab Francesco Grossi U.O.S. Tumori
More information1st line chemotherapy and contribution of targeted agents
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy
More informationMaintenance Treatment of Advanced NSCLC
Maintenance Treatment of Advanced NSCLC Giorgio V. Scagliotti University of Torino Department of Clinical & Biological Sciences giorgio.scagliotti@unito.it UNIVERSTY OF TORINO DEPT. OF OF Maintenance /Consolidation/Sequencing
More information1st-line Chemotherapy for Advanced disease
SESSION 3: ADVANCED NSCLC 1st-line Chemotherapy for Advanced disease JY DOUILLARD MD PhD Professor Emeritus in Medical Oncology Chief Medical Officer (CMO) ESMO Lugano CH Percent Survival HISTORICAL BASIS
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationManagement Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationPersonalized maintenance therapy in advanced non-small cell lung cancer
China Lung Cancer Research Highlight Personalized maintenance therapy in advanced non-small cell lung cancer Kazuhiro Asami, Kyoichi Okishio, Tomoya Kawaguchi, Shinji Atagi Department of Clinical Oncology,
More information1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC
1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC Dr Ross Soo, FRACP National University Cancer Institute, Singapore National University Health System Cancer Science
More informationin combination with cisplatin as first-line doublet 3 as maintenance agent following non-pemetrexed platinum doublet 4
Overall survival (OS) results from PARAMOUNT study of maintenance plus best supportive care (BSC) versus plus BSC, immediately after induction with - Cisplatin, in patients with advanced Nonsquamous Non-small
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME. 1 st line chemotherapy for advanced NSCLC. Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine
ESMO THE CHRISTIE PRECEPTORSHIP PROGRAMME 1 st line chemotherapy for advanced NSCLC Benjamin BESSE, MD, PhD Head Dpt of Cancer Medicine 2017 PD-L1 50% Pembrolizuma b [I,A] Courtesy of J.Remon Adapted from
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationRecent Therapeutic Advances for Thoracic Malignancies
Recent Therapeutic Advances for Thoracic Malignancies Developed in collaboration Learning Objectives Upon completion, participants should be able to: Interpret new developments in the use of radiation
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationSecond-line treatment for advanced NSCLC
UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Life was so simple back in 2008 Di
More informationNSCLC: immunotherapy as a first-line treatment. Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To)
NSCLC: immunotherapy as a first-line treatment Paolo Bironzo Oncologia Polmonare AOU S. Luigi Gonzaga Orbassano (To) The 800-pound gorilla Platinum-based chemotherapy is the SOC for 1st-line therapy in
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationConversations in Oncology. November Kerry Hotel Pudong, Shanghai China
Conversations in Oncology November 12-13 Kerry Hotel Pudong, Shanghai China Immunotherapy of Lung Cancer Professor Caicun Zhou All materials are for scientific exchanges. Afatinib and nintedanib are not
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationEGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS
EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS Federico Cappuzzo Istituto Clinico Humanitas IRCCS Rozzano-Italy The EGFR/HER Family Ligand binding domain
More informationNSCLC with squamous histology: Current treatment and new options on horizon
NSCLC with squamous histology: Current treatment and new options on horizon Prof. Yasser A.Kader Professor of Oncology Faculty of Medicine, Cairo University 2015 Lung Cancer: Incidence and Mortality New
More informationBackground. Azzoli CG et al. J Clin Oncol 2009; 2 Sandler A et al. NEJM 2006; 3
A Randomized, Open-Label, Phase III, Superiority Study of Pemetrexed(Pem) + Carboplatin(Cb) + Bevacizumab(Bev) Followed by Maintenance Pem + Bev versus Paclitaxel (Pac)+Cb+Bev Followed by Maintenance Bev
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationINNOVATION IN LUNG CANCER MANAGEMENT. Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy
INNOVATION IN LUNG CANCER MANAGEMENT Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy FIRST-LINE THERAPY FOR METASTATIC NSCLC IN 216 Stratification for EGFR, ALK
More informationCytotoxic Maintenance Therapy in Advanced NSCLC: Update State of the Art or State of Confusion
Cytotoxic Maintenance Therapy in Advanced NSCLC: Update State of the Art or State of Confusion Corey J Langer MD, FACP Director Thoracic Oncology Abramson Cancer Center Professor of Medicine Hematology-Oncology
More information11/21/2009. Erlotinib in KRAS Mt patients. Bevacizumab in Squamous patients
Decision-Making in Non-Small Cell Lung Cancer (NSCLC): Moving from Empiric to Personalized & Molecular-based Therapy David R. Gandara, MD University of California Davis Cancer Center Disclosures Research
More informationTratamiento de la enfermedad avanzada en cáncer de pulmón
Tratamiento de la enfermedad avanzada en cáncer de pulmón S. Ponce Aix! S. Oncología Médica Hospital Universitario 12 de Octubre Madrid Survival by stage NSCLC Stage Distribution NSCLC Stage 5-year Survival
More informationIs there a role for maintenance therapy in advanced non-small-cell lung cancer?
Review Is there a role for maintenance therapy in advanced non-small-cell lung cancer? Cesare Gridelli*1, Paolo Maione1, Antonio Rossi1, Clorinda Schettino1, Maria Anna Bareschino1, Paola Claudia Sacco1,
More informationSuccesses and Challenges in Treating Squamous Cell Carcinoma of the Lung
Successes and Challenges in Treating Squamous Cell Carcinoma of the Lung Noemi Reguart,MD, PhD Hospital Clinic de Barcelona Barcelona, Spain SC-CRP-02660 Conversations in Oncology 2018 is a standalone
More informationINMUNOTERAPIA I. Dra. Virginia Calvo
INMUNOTERAPIA I Dra. Virginia Calvo LBA62. Health-related quality of life (HRQoL) for Pembrolizumab or placebo plus Carboplatin and Paclitaxel or nab-paclitaxel in patients with metastatic squamous NSCLC:
More informationUnderstanding Options: When Should TKIs be Considered?
Advanced Stage Squamous NSCLC: Evolution and Increasing Complexity of the Therapeutic Landscape Understanding Options: When Should TKIs be Considered? David R. Gandara, MD University of California Davis
More informationK-Ras signalling in NSCLC
Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
More informationAngiogenesis and tumor growth
Anti-angiogenic agents: where we are? Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Angiogenesis and tumor growth Journal of experimental Medicine 1972; 133: 275-88 1 Angiogenesis
More informationPERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER. Virginie Westeel Chest Disease Department University Hospital Besançon, France
PERIOPERATIVE TREATMENT OF NON SMALL CELL LUNG CANCER Virginie Westeel Chest Disease Department University Hospital Besançon, France LEARNING OBJECTIVES 1. To understand the potential of perioperative
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Data on first-line Overcoming T790M
More informationImmunoterapia di 1 linea Evidenze e Prospettive Future
Immunoterapia di 1 linea Evidenze e Prospettive Future Sara Pilotto Oncologia Medica, Dipart. di Medicina, Università di Verona, A.O.U.I. Verona sara.pilotto@univr.it Negrar, 30 ottobre 2018 Disclosures
More informationPersonalized Medicine for Advanced NSCLC in East Asia
Personalized Medicine for Advanced NSCLC in East Asia - Update treatment strategy for NSCLC based on Japanese clinical practice guideline - Masahiro Tsuboi, M.D., Ph.D. Associate-professor, School of Medicine,
More informationSecond-line treatment for advanced NSCLC
Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY DISCLOSURE OF INTEREST Speaker Bureau: Eli Lilly, MSD, BI, BMS, Roche, AZ UNIVERSITY
More informationChanging demographics of smoking and its effects during therapy
Changing demographics of smoking and its effects during therapy Egbert F. Smit MD PhD. Dept. Pulmonary Diseases, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands Smoking prevalence adults
More informationASCO Highlights Lung Cancer
ASCO Highlights Lung Cancer Anne S. Tsao, M.D. Director, Mesothelioma Program Assistant Professor July 11, 2009 The University of Texas MD ANDERSON CANCER CENTER Department of Thoracic/Head & Neck Medical
More informationQuale sequenza terapeutica nella malattia EGFR+
Trattamento della malattia avanzata oncogene-addicted Quale sequenza terapeutica nella malattia EGFR+ Chiara Bennati AUSL della Romagna Ravenna, Italy A matter of fact Outline Can we improve PFS/OS with
More informationVEGF-Inhibitors in NSCLC. Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany
VEGF-Inhibitors in NSCLC Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Conflicts of interest Advisory Board: AstraZeneca Bristol-Myers Squibb Daiichi Sankyo Eli Lilly Merck
More informationCURRENT STANDARD OF CARE OF LUNG CANCER. Maroun El-Khoury, MD Consultant Oncologist/Hematologist American Hospital Dubai President of Medical staff
CURRENT STANDARD OF CARE OF LUNG CANCER Maroun El-Khoury, MD Consultant Oncologist/Hematologist American Hospital Dubai President of Medical staff Biopsy: Establish Diagnosis, Determine Histologic Subtype,
More informationDo You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement. Reference Slides Introduction
Do You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement Reference Slides Introduction EML4-ALK Fusion Oncogene Key Driver in 3% to 7% NSCLC Inversion or Translocation
More informationSequencing in EGFR-Mutated NSCLC: Does Order Matter?
Sequencing in EGFR-Mutated NSCLC: Does Order Matter? Maximilian J. Hochmair, MD Otto Wagner Hospital Vienna, Austria Disclosures Honoraria: AstraZeneca, AbbVie, Pfizer, Boehringer Ingelheim, Roche, MSD,
More informationLUNG CANCER. Başak Oyan-Uluç, MD Yeditepe University Hospital Medical Oncology. Best of ASCO, İstanbul
LUNG CANCER Başak Oyan-Uluç, MD Yeditepe University Hospital Medical Oncology Best of ASCO, İstanbul 2012 23.6.2012 Treatment of Metastatic NSCLC EGFR targetted treatments 1st line: EGFR-mutated: Afatinib
More informationCurrent Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018
Current Issues in Checkpoint Immunotherapy for NSCLC: A Perspective from January 2018 David R. Gandara, MD University of California Davis Comprehensive Cancer Center Disclosures Research Grants: AstraZeneca/Medi,
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationOverview of Lung Cancer :Perspectives from Cancer Genotype. Ji-Youn Han, MD, PhD. Center for Lung Cancer National Cancer Center
Overview of Lung Cancer :Perspectives from Cancer Genotype Ji-Youn Han, MD, PhD. Center for Lung Cancer National Cancer Center Histologic classification of lung cancer Therapeutic plateau reached with
More informationNon-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist
Non-small Cell Lung Cancer: Multidisciplinary Role: Role of Medical Oncologist Vichien Srimuninnimit, MD. Medical Oncology Division Faculty of Medicine, Siriraj Hospital Outline Resectable NSCLC stage
More informationCancer Cell Research 14 (2017)
Available at http:// www.cancercellresearch.org ISSN 2161-2609 Efficacy and safety of bevacizumab for patients with advanced non-small cell lung cancer Ping Xu, Hongmei Li*, Xiaoyan Zhang Department of
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationCarcinoma escamoso: optimizacio n de tratamiento. Noemi Reguart Hospital Clínic Barcelona
Carcinoma escamoso: optimizacio n de tratamiento Noemi Reguart Hospital Clínic Barcelona National Cancer Database (US) 80% 70% 60% 50% 40% 30% Incidence of SCC 27% 20% 10% 0% 1998-1999 2000-2003 2004-2007
More informationPATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER
PATIENT SELECTION CORRELATION OF PD-L1 EXPRESSION AND OUTCOME? THE ONCOLOGIST VIEW ON LUNG CANCER Martin Reck Department of Thoracic Oncology LungClinic Grosshansdorf Germany DISCLOSURES Honoraria for
More informationStrategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors
Strategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors Miklos Pless Medical Oncology Kantonsspital Winterthur 2 Setting the stage. 1995: Chemotherapy works! Meta-Analysis
More informationMonoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs
Monoclonal Antibodies in the Management of Non-Small Cell Lung Cancer (NSCLC): 2016 Update Angioinhibitors and EGFR MAbs Corey J Langer, MD, FACP Director Thoracic Oncology Abramson Cancer Center Professor
More informationImmunotherapeutic Approaches in the Treatment of NSCLC. Keith Kerr, MBChB, FRCPath. Aberdeen Royal Infirmary
01 Immunotherapeutic Approaches in the Treatment of NSCLC Keith Kerr, MBChB, FRCPath. Aberdeen Royal Infirmary Outline 02 Review the concept and evolution of immunotherapy in the treatment of cancer Discuss
More informationLUNG CANCER TREATMENT: AN OVERVIEW
LUNG CANCER TREATMENT: AN OVERVIEW KONSTANTINOS N. SYRIGOS, M.D., Ph.D. Αναπλ. Καθηγητής Παθολογίας-Ογκολογίας, Ιατρικής Σχολής Αθηνών. Διευθυντής Ογκολογικής Μονάδας, Νοσ. «Η Σωτηρία». Visiting Professor
More informationImmunotherapies for Advanced NSCLC: Current State of the Field. H. Jack West Swedish Cancer Institute Seattle, Washington
Immunotherapies for Advanced NSCLC: Current State of the Field H. Jack West Swedish Cancer Institute Seattle, Washington Nivolumab in Squamous NSCLC Chemo-pretreated (1 st line) Adv squamous NSCLC N =
More informationTarget therapy nel NSCLC con EGFR M+ Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy)
Target therapy nel NSCLC con EGFR M+ Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy) cgridelli@libero.it First-Line Treatment of Advanced NSCLC EGFR-mutation analysis
More informationPatient Selection: The Search for Immunotherapy Biomarkers
Patient Selection: The Search for Immunotherapy Biomarkers Mark A. Socinski, MD Executive Medical Director Florida Hospital Cancer Institute Orlando, Florida Patient Selection Clinical smoking status Histologic
More informationBest of ASCO 2014 Lung
Best of ASCO 214 Lung Heather Wakelee, MD Associate Professor of Medicine, Oncology Stanford Cancer Institute Stanford, California USA Outline ALK: 82: 1st line crizotinib Profile 114 83: ASCEND ceritinib
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationMedical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
More informationEstado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico
Estado actual del tratamiento neoadyuvante y adyuvante a la cirugía en estadios iniciales de cáncer de pulmón no microcítico Enriqueta Felip Vall d Hebron University Hospital Barcelona, Spain Stage I-II
More informationWeitere Kombinationspartner der Immunotherapie
1 Weitere Kombinationspartner der Immunotherapie Rolf Stahel University Hospital of Zürich Zürich, 9.12.216 2 Immunotherapy in a multimodality approach NSCLC Advanced disease Checkpoint inhibitors for
More informationAgenda. 6:30pm 7:00pm. Dinner. 7:00pm 7:15pm. NSCLC Treatment in 2014: Focus on Use of 2nd Generation TKIs in Clinical Practice.
Agenda 6:30pm 7:00pm Dinner 7:00pm 7:15pm Welcome and Introductions Natasha Leighl, MD 7:15pm 7:50pm 7:50pm 8:00pm NSCLC Treatment in 2014: Focus on Use of 2nd Generation TKIs in Clinical Practice Questions
More informationCollaborative Practice in the Management of Patients With Cancer. Non-Small Cell Lung Cancer: Management of Patients on Cytotoxic Chemotherapy
Collaborative Practice in the Management of Patients With Cancer Non-Small Cell Lung Cancer: Management of Patients on Cytotoxic Chemotherapy Program Chair Beth Eaby-Sandy, MSN, CRNP, OCN Abramson Cancer
More informationSequence or intercalation of use of targeted agents and Chemotherapy Definition of progression under TKI
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER Strategic Approaches Sequence or intercalation of use of targeted agents and Chemotherapy Definition of progression under TKI Yi-Long Wu Guangdong
More informationImmune checkpoint inhibitors in NSCLC
1 Immune checkpoint inhibitors in NSCLC Rolf Stahel University Hospital of Zürich Zürich, November 3, 2017 2 What can we learn from the clinical experience of second line immunotherapy of advanced NSCLC?
More informationLung cancer is the leading cause of cancer-related death in the
ORIGINAL ARTICLE Bevacizumab Maintenance in Patients with Advanced Non Small-Cell Lung Cancer, Clinical Patterns, and Outcomes in the Eastern Cooperative Oncology Group 4599 Study Results of An Exploratory
More informationBiomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard
More informationTreatment of advanced NSCLC in the elderly. Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy)
Treatment of advanced NSCLC in the elderly Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy) Most cancer patients are aged >65 years Ovary Breast NHL Corpus uteri Leukaemias
More informationLudger Sellmann 1, Klaus Fenchel 2, Wolfram C. M. Dempke 3,4. Editorial
Editorial Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer the Holy Grail in cancer treatment? Ludger Sellmann 1, Klaus Fenchel
More informationRecent Therapeutic Advances in Squamous Cell Carcinoma of the Lung
Recent Therapeutic Advances in Squamous Cell Carcinoma of the Lung 2017 Conversations in Oncology in Shanghai, China Prof. Shun Lu Shanghai Lung Cancer Center Shanghai Chest Hospital Affiliated to Medical
More informationContemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer
Contemporary Chemotherapy-Based Strategies for First-Line Metastatic Breast Cancer Hope S. Rugo, MD Professor of Medicine Director, Breast Oncology and Clinical Trials Education University of California
More informationExploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
More information2012 Chicago Multidisciplinary Symposium in Thoracic Oncology September 6-8, 2012 Friday, September 7, News Briefing 7:15 a.m.
2012 Chicago Multidisciplinary Symposium in Thoracic Oncology September 6-8, 2012 Friday, September 7, News Briefing 7:15 a.m. Central time Moderated by Heather Wakelee, MD Stanford University Stanford,
More informationErlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy
Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy September 2008 This technology summary is based on information available at the time of research and a
More informationMaintenance therapies in advanced non-small-cell lung cancer
Review Maintenance therapies in advanced non-small-cell lung cancer Advanced non-small-cell lung cancer is treated with upfront platinum doublet chemotherapy, which produces moderate survival improvements.
More informationNew Options for Achieving Individualized Approaches to Non-Small Cell Lung Cancer (NSCLC) Management
New Options for Achieving Individualized Approaches to Non-Small Cell Lung Cancer (NSCLC) Management Ramaswamy Govindan, MD Director Professor of Medicine Director, Thoracic Oncology Program Department
More information